February 18, 2025 10:46 AM EST
News Briefing

Septer­na ends Phase 1 tri­al for hy­poparathy­roidism drug; Sanofi’s Mer­ilog is ap­proved

ENDPOINTS

Plus, news about Basilea, TME Phar­ma and Per­ceive Bio­ther­a­peu­tics:

Septer­na stops work on Phase 1: The new­ly pub­lic biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

As part of turn­around, Sol­id Bio re­ports promis­ing ini­tial da­ta for Duchenne gene ther­a­py

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

Ar­cus touts ear­ly kid­ney can­cer da­ta as Gilead de­clines op­tion

Ex­clu­sive: Atom­wise, a once high-fly­ing AI start­up, taps biotech vet as CEO to lead pared-down com­pa­ny

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times